A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread

Treatment Patterns and Outcomes in Unresectable or Metastatic Renal Cell Carcinoma (mRCC) Patients in Japan

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03161145

Enrollment

297

Registered

2017-05-19

Start date

2016-12-09

Completion date

2017-08-31

Last updated

2017-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Brief summary

A medical review chart study in Japan to describe the treatment patterns and outcomes of patients with kidney cancer that is unable to be removed by surgery or that has spread. The clinical data is to be abstracted using electronic data capture (eDC) from patient medical records in Japan.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Adults 20 years and older at the time of initial diagnosis of mRCC * Alive or deceased as of the date of data collection * Diagnosis of mRCC between 01-Jan-2012 and 31-Aug-2015

Exclusion criteria

* Previously and/or currently enrolled in RCC clinical trials * Patients have primary cancer other than renal cell cancer

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	Approximately 2 years	measured by data collection in years
Treatment patterns	Approximately 5 years	measured by retrospective data collection of treatment regimen and duration (including rate of permanent and temporary discontinuation)
Reason for terminating or switching treatment	Approximately 5 years	measured by data collection information available in retrospective analysis, if disclosed
Adverse Events	Approximately 5 years	measured by data collection

Countries

Japan

Outcome results